CADD522 是一种 RUNX2-DNA 结合抑制剂,通过下调 RUNX2 介导的下游靶基因转录发挥作用,其 IC50 值为 10 nM,还可通过增加线粒体驱动的细胞 ROS 水平发挥抗肿瘤活性,并能抑制体内原发肿瘤的生长以及免疫受损小鼠肺部肿瘤细胞的实验性转移,可用于癌症研究。
产品编号: MS-Q81323 纯度: 98.23% CAS No.: 199735-88-1 分子式: C15H13Cl2NO3 分子量: 326.17
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

CADD522 是一种 RUNX2-DNA 结合抑制剂,通过下调 RUNX2 介导的下游靶基因转录发挥作用,其 IC50 值为 10 nM,还可通过增加线粒体驱动的细胞 ROS 水平发挥抗肿瘤活性,并能抑制体内原发肿瘤的生长以及免疫受损小鼠肺部肿瘤细胞的实验性转移,可用于癌症研究。

生物实验数据

生物活性 CADD522 is a RUNX2-DNA binding inhibitor (downregulating the transcription of RUNX2-mediated downstream target genes) with an IC50 value of 10 nM that also exerts its antitumor activity by increasing mitochondria-driven cellular ROS levels, inhibits the growth of primary tumors in vivo and the experimental metastasis of lung tumor cells in immunocompromised mice, and can be used for cancer research.
IC50 & Target RUNX2:10 nM
体外研究
(In Vitro)

CADD522 (0-100 μM; 24-72 h) 对 BC 细胞生长和存活表现出强烈的抑制作用。
CADD522 (50 μM;72 h) 通过诱导细胞周期停滞(G1 期)显示出抗增殖作用。
CADD522 (50 μM;8 days) 抑制肿瘤球形成和(50 μM;24 h)体外 BC 细胞侵袭(无细胞毒性。
CADD522 (2、10、25、50、100 μM;48 h) 通过抑制 T47D-RUNX2 和 T47D-Empty 细胞中的 RUNX2-DNA 结合来抑制 RUNX2 转录活性。
CADD522 (50 μM;72 h) 通过增加细胞中 RUNX2 的稳定性上调 RUNX2 水平。
/> CADD522 (50 μM;6 or 24 h) 增加 MCF7 和 MDA-468 细胞中线粒体的 ROS 生成。
CADD522 (0 -2000 nM,30 min) 抑制 MDA-231 和 MDA-468 细胞中的线粒体 ATP 合酶活性。

Cell Viability Assay

Cell Line: MDA-MB-468, MCF7, MCF10A, IEC-6, GES-1 and C2C12 cells
Concentration: 0-100 μM
Incubation Time: 24-72 h
Result: Displayed a dose- and time-dependent cell growth inhibition over 72 h.
Exhibited low cytotoxicity for normal cell growth.

Cell Cycle Analysis

Cell Line: MCF7, MDA-468 and MDA-231 cells
Concentration: 50 μM
Incubation Time: 72 h
Result: Induced MDA-231 cells accumulated at the G1 and G2/M phase whereas MCF7 and MDA-468 cells were at the G1 phase.

Cell Viability Assay

Cell Line: MCF7, MCF7-tet-off cells
Concentration: 50 μM
Incubation Time: 8 days
Result: Dramatically decreased the size as well as the number of tumorspheres, and severely disrupted tumorspheres at day 4.
Showed a relatively selective effect on BC cells (did not have a significant influence on mammosphere formation of the MCF10A non-malignant mammary epithelial cells).

Cell Invasion Assay

Cell Line: MCF7-tet-off (+Doxy), MCF7-tet-off (-Doxy) cells
Concentration: 50 μM
Incubation Time: 24 h
Result: Almost abrogated the invasiveness of both MCF7-tet-off (+Doxy) and MCF7-tet-off (-Doxy) cells without cellular toxicity.

Cell Viability Assay

Cell Line: T47D-RUNX2 and T47D-Empty cells
Concentration: 2, 10, 25, 50, 100 μM
Incubation Time: 48 h
Result: Resulted in a dramatic decrease of the promoter-luciferase (Luc) activities of RUNX2 downstream target genes such as MMP13 and VEGF (metastasis markers) and OC (osteogenesis marker).

RT-PCR

Cell Line: T47D and MCF7 cells (ectopic expressing RUNX2)
Concentration: 50 μM
Incubation Time: 72 h
Result: Significantly inhibited the mRNA level (RUNX2-mediated) of Glut-1 and LDHA.

Western Blot Analysis

Cell Line: T47D-RUNX2 and MCF7-RUNX2 cells
Concentration: 50 μM
Incubation Time: 72 h
Result: Enhanced both mRNA and protein expression of RUNX2.

Western Blot Analysis

Cell Line: MDA-468 and MDA-231 cells
Concentration: 50 μM
Incubation Time: 2, 4, 6 h
Result: Increased RUNX2 stability by delaying protein degradation.

Cell Viability Assay

Cell Line: MCF7 and MDA-468 cells
Concentration: 50 μM
Incubation Time: 6 or 24 h
Result: Increased the level of mitochondrial ROS, which was more evident in serum-free than serum-containing condition.

Cell Viability Assay

Cell Line: MDA-231 and MDA-468 cells
Concentration: 50, 250, 2000 nM (for MDA-231); 500, 2000 nM (for MDA-468)
Incubation Time: 30 min
Result: Inhibited the activity of A TP synthase.
体内研究
(In Vivo)

CADD522 (1、5 和 20 mg/kg;腹腔注射;每周两次,持续 45 天) 延缓肿瘤的发生并抑制小鼠肿瘤的生长。
CADD522 (10 mg/kg;腹腔注射;每周两次,持续 11 天) 抑制肿瘤转移并抑制小鼠 Ki-67 的表达。

Animal Model: Female mice (6-week-old; MMTV-PyMT transgenic model).
Dosage: 1, 5 and 20 mg/kg
Administration: Intraperitoneal injection; twice a week for 45 days.
Result: Delayed the onset of the tumors, delayed tumor development and reduced tumor burden in transgenic MMTV-PyMT mice.
Reduced the tumor weight in mice.
Animal Model: Female NOD scid gamma (NSG) mice and nude mice (TNBC-PDX Br-001 model).
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; twice a week for 11 days.
Result: Significant decreased tumor volume and markedly inhibited expression of Ki-67.
Inhibited experimental metastasis of BC cells in vivo.(did not significantly decrease body weight or influence the general health of animals).
性状 固体
颜色 White to off-white

化学信息

分子量 326.17
分子式 C15H13Cl2NO3
CAS No. 199735-88-1

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10.00 mg/mL (30.66 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.00 mg/mL (15.33 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (306.59 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0659 mL15.3294 mL30.6589 mL76.6471 mL
5 mM0.6132 mL3.0659 mL6.1318 mL15.3294 mL
10 mM0.3066 mL1.5329 mL3.0659 mL7.6647 mL
15 mM0.2044 mL1.0220 mL2.0439 mL5.1098 mL
20 mM0.1533 mL0.7665 mL1.5329 mL3.8324 mL
25 mM0.1226 mL0.6132 mL1.2264 mL3.0659 mL
30 mM0.1022 mL0.5110 mL1.0220 mL2.5549 mL
40 mM0.0766 mL0.3832 mL0.7665 mL1.9162 mL
50 mM0.0613 mL0.3066 mL0.6132 mL1.5329 mL
60 mM0.0511 mL0.2555 mL0.5110 mL1.2775 mL
80 mM0.0383 mL0.1916 mL0.3832 mL0.9581 mL
100 mM0.0307 mL0.1533 mL0.3066 mL0.7665 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础